Healthcare Industry News: ALZA Corp
News Release - January 5, 2006
Ilypsa Announces Appointment of Jay P. Shepard as President and CEOSANTA CLARA, Calif.--(HSMN NewsFeed)--Jan. 5, 2006--Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders, today announced the appointment of Jay P. Shepard as President and Chief Executive Officer. Mr. Shepard will also join the company's board of directors.
"Ilypsa has assembled an outstanding team, which I am honored to lead. This company has gone to IND in a little over two years with its first compound, ILY101, a novel polymeric phosphate binder," stated Mr. Shepard. "This is an extraordinary business opportunity -- uniting a validated discovery engine with a pipeline of novel pharmaceutical agents that have reduced clinical risk and short development timelines, a combination rarely seen in our industry."
Mr. Shepard brings more than 20 years of experience in pharmaceutical, biotechnology and drug delivery product commercial operations and management. Prior to joining Ilypsa, Mr. Shepard served as Vice President, Commercial Operations at Telik, Inc., where he was responsible for all activities relating to market preparation towards launch of the company's lead oncology compounds. Previously, Mr. Shepard was Vice President of ALZA Pharmaceuticals' Oncology Business Unit, having held positions of increasing responsibility in the establishment and operations of ALZA Corporations' specialty pharmaceutical sales and marketing group. Mr. Shepard began his career in pharmaceutical sales and marketing at Ortho Pharmaceutical Corporation and Syntex Laboratories.
"We are very pleased that Jay Shepard has joined the team. Jay's distinguished track record in working early on with leading biopharmaceutical companies to design and implement successful commercial strategies made him a natural choice for Ilypsa. His experience in building commercial organizations as well as successful products will be invaluable as Ilypsa continues to deliver on key milestones toward human proof of concept for multiple development compounds," commented Scott Rocklage, Ph.D., Executive Chairman of Ilypsa.
About Ilypsa, Inc.
Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a pipeline of next-generation renal care pharmaceutical products. Pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies, Inc. (Nasdaq:SMMX ), Ilypsa has rapidly created non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney and metabolic diseases. To date, Ilypsa has raised $46 million in a Series A and a Series B round of financing. Investors include NLV Partners, 5AM Ventures, US Venture Partners, Johnson & Johnson Development Corporation and Delphi Ventures. For more information, please visit www.ilypsa.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.